Astria Therapeutics (NASDAQ:ATXS) Sees Strong Trading Volume

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) saw unusually-strong trading volume on Wednesday . Approximately 582,102 shares traded hands during trading, a decline of 41% from the previous session’s volume of 994,370 shares.The stock last traded at $12.93 and had previously closed at $13.53.

Analysts Set New Price Targets

ATXS has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Astria Therapeutics in a research report on Monday. Jefferies Financial Group lifted their price objective on shares of Astria Therapeutics from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Monday. Finally, Wedbush reissued an “outperform” rating and set a $17.00 target price on shares of Astria Therapeutics in a research report on Tuesday.

Astria Therapeutics Stock Up 3.5 %

The business has a 50-day simple moving average of $13.68 and a 200-day simple moving average of $8.79. The stock has a market cap of $772.72 million, a P/E ratio of -6.01 and a beta of 0.72.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings results on Monday, March 4th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). On average, analysts predict that Astria Therapeutics, Inc. will post -1.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Astria Therapeutics

In other Astria Therapeutics news, Director Perceptive Advisors Llc purchased 2,481,350 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was bought at an average cost of $12.09 per share, for a total transaction of $29,999,521.50. Following the completion of the acquisition, the director now directly owns 4,873,721 shares in the company, valued at $58,923,286.89. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Perceptive Advisors Llc acquired 2,481,350 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were bought at an average price of $12.09 per share, for a total transaction of $29,999,521.50. Following the acquisition, the director now owns 4,873,721 shares in the company, valued at approximately $58,923,286.89. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Christopher Morabito sold 9,200 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $11.15, for a total transaction of $102,580.00. The disclosure for this sale can be found here. Insiders own 3.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ATXS. Vanguard Group Inc. boosted its stake in Astria Therapeutics by 36.1% during the fourth quarter. Vanguard Group Inc. now owns 2,055,707 shares of the biotechnology company’s stock worth $15,788,000 after buying an additional 545,786 shares in the last quarter. American International Group Inc. raised its position in Astria Therapeutics by 29.0% in the fourth quarter. American International Group Inc. now owns 16,443 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 3,694 shares in the last quarter. Perceptive Advisors LLC lifted its stake in Astria Therapeutics by 82.9% during the fourth quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock worth $30,751,000 after purchasing an additional 1,814,608 shares during the period. Legal & General Group Plc boosted its holdings in Astria Therapeutics by 34.4% during the fourth quarter. Legal & General Group Plc now owns 3,492 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 894 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Astria Therapeutics by 487.0% in the 4th quarter. Barclays PLC now owns 49,414 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 40,996 shares during the period. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.